The Gastroesophageal Reflux Disease Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Gastroesophageal Reflux Disease Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

According to The Business Research Company’s Gastroesophageal Reflux Disease Therapeutics Global Market Report 2024, The gastroesophageal reflux disease therapeutics market size has grown steadily in recent years. It will grow from $5.78 billion in 2023 to $6 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to changing lifestyles and dietary habits, aging population, increased awareness and diagnosis, prevailing stressful lifestyles, rise in obesity rates..

The gastroesophageal reflux disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $7.33 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to rise in demand for novel therapies, growing geriatric population, personalized medicine approaches, focus on non-pharmacological interventions, emergence of biologics and innovative therapies.. Major trends in the forecast period include alternative therapies and mind-body practices, expanded research into gut health, advent of patient-centric care models, targeted marketing for gerd awareness, integration of digital health tools..

The prevalence of gastroesophageal reflux disease is expected to propel the growth of the gastroesophageal reflux disease therapeutics market moving forward. Gastroesophageal reflux disease is a chronic condition characterized by the backflow of stomach acid into the esophagus, causing symptoms such as heartburn, regurgitation, and potential complications. The gastroesophageal reflux disease (GERD) therapeutics help in reducing and managing the symptoms of acid reflux by neutralizing the pH of the gut, controlling inflammation, and improving esophageal function. For instance, in September 2022, according to the article published by WebMed, a US-based online publisher of news and information about human health, more than 60 million American adults suffer heartburn at least once a month, and more than 15 million suffer daily. Furthermore, in July 2022, statistics shared by the National Library of Medicine, a US-based federal medical library, GERD is one of the most often diagnosed digestive illnesses in the United States, with a 20% prevalence, resulting in a significant economic burden in direct and indirect expenditures as well as a negative impact on quality of life. Therefore, the prevalence of gastroesophageal reflux disease is expected to drive the growth of the gastroesophageal reflux disease therapeutics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp

The gastroesophageal reflux disease therapeutics market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets
4) By Application: Crohn’s Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis

Top Major Players
Pfizer Inc.
Johnson and Johnson
Novartis AG
Sanofi S.A.
AstraZeneca PLC

Product innovations are the key trend gaining popularity in the gastroesophageal reflux disease therapeutics market. Major companies operating in the gastroesophageal reflux disease therapeutics market are focusing on innovative medications to sustain their position in the market. For instance, in March 2021, Xiromed LLC, a US-based integrated generic company, launched Omeprazole Delayed-Release Capsules (generic to Prilosec) to treat frequent heartburn in gastroesophageal reflux. Omeprazole is a proton pump inhibitor (PPI) medication designed to treat some stomach and esophageal issues (such as acid reflux and ulcers) by lowering the quantity of acid produced by the stomach that alleviating symptoms such as heartburn, trouble swallowing, and persistent cough. This drug helps cure acid damage to the stomach and esophagus, prevents ulcers, and may help prevent oesophageal cancer.

The gastroesophageal reflux disease therapeutics market report table of contents includes:
1. Executive Summary
2. Gastroesophageal Reflux Disease Therapeutics Market Characteristics
3. Gastroesophageal Reflux Disease Therapeutics Market Trends And Strategies
4. Gastroesophageal Reflux Disease Therapeutics Market - Macro Economic Scenario
5. Global Gastroesophageal Reflux Disease Therapeutics Market Size and Growth
..........................
32. Global Gastroesophageal Reflux Disease Therapeutics Market Competitive Benchmarking
33. Global Gastroesophageal Reflux Disease Therapeutics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Gastroesophageal Reflux Disease Therapeutics Market
35. Gastroesophageal Reflux Disease Therapeutics Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model